CDP 855

Drug Profile

CDP 855

Latest Information Update: 21 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech R&D
  • Class Antirheumatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 01 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D
  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
  • 22 Oct 1999 Celltech has merged with Chiroscience to form Celltech Chiroscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top